Bokf Na Has $342,000 Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Bokf Na lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 23.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,316 shares of the biopharmaceutical company’s stock after purchasing an additional 1,580 shares during the quarter. Bokf Na’s holdings in Ultragenyx Pharmaceutical were worth $342,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Headlands Technologies LLC bought a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth about $28,000. nVerses Capital LLC acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $33,000. UMB Bank n.a. lifted its holdings in Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 352 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Ultragenyx Pharmaceutical by 622.3% during the 1st quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 865 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Ultragenyx Pharmaceutical by 67.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 1,339 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $59.36 on Tuesday. The firm has a market capitalization of $5.47 billion, a PE ratio of -7.39 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $31.52 and a fifty-two week high of $60.37. The company’s 50-day moving average is $50.83 and its 200 day moving average is $46.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The firm had revenue of $147.03 million for the quarter, compared to analysts’ expectations of $123.20 million. During the same quarter last year, the firm earned ($2.25) EPS. The company’s quarterly revenue was up 35.7% compared to the same quarter last year. As a group, analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RARE. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, July 23rd. The Goldman Sachs Group upped their price objective on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Wedbush upped their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Monday. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $87.43.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 40,675 shares of company stock worth $2,149,446. 5.80% of the stock is owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.